US FDA announces major recall of over 67,000 cases of Power Stick deodorant
The FDA and A.P. Deauville issued a voluntary recall of over 67,000 cases of Power Stick deodorant last week that were sold across the country. The recall notice didn't specify the exact nature of issue that has taken place in the deodorant but stated that it is related to deviations with 'current good manufacturing practices' (cGMP).
The recall was issued on July 10 and includes over 21,200 cases of the brand's 'power fresh'-scented Power Stick for Her Roll-On Antiperspirant Deodorant, over 22,400 cases of its 'spring fresh' scented Power Stick Invisible Protection Roll-On Antiperspirant Deodorant and over 23,400 cases of Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant.
The Easton, Pennsylvania based company has not issued a statement regarding the recall of its products. A report by The Independent stated that the deodorant was available for purchase on Walmart for a pack of three for $21, and a pack of 24 deodorants was available on Dollar Tree for $30. E-commerce giant Amazon was also selling the product.
The affected lot numbers for Power Stick for her roll-on Antiperspirant Deodorant are:
032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341, 082826E402
The lot numbers for the affected Power Stick Invisible Protection Roll-On Antiperspirant Deodorant are:
031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391, 111626G231
And the affected lot numbers for Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant are:
101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091, 111626G221.
Among the other SKUs in the personal care category, A.P. Deauville manufactures shampoos, conditioners, lotions, body washes, and facial wipes.
(with inputs from The Independent)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
4 hours ago
- New Indian Express
All Ayush medicines now to be brought under FDA: Karnataka Health Minister Dinesh Gundu Rao
BENGALURU: Karnataka Health Minister Dinesh Gundu Rao said on Monday that all medicines under the Department of Ayush, including those in Ayurvedic, Unani, Siddha, and Homeopathy streams, will now be brought under the drugs control wing of the Food Safety and Drug Administration (FDA). Addressing reporters here, he said this is specifically to improve the quality of traditional medicines. He said the Health Department has reduced the time it took to recall substandard medicines from the market. Earlier, once a drug was flagged as Not of Standard Quality (NSQ), it could take up to 30 days to take it back from pharmacies and distributors. Now, that time has been cut to just two days. Rao said this is crucial because such medicines, if left on shelves, may continue to be taken by patients, posing serious health risks. In June alone, drugs worth Rs 40.48 lakh that did not meet the safety standards were recalled and seized across the state. The department noted that in July, 1,433 drug samples were analysed by laboratories in Bengaluru, Hubballi and Ballari. Of them, 67 were found to be substandard with the department filing 29 cases. A special enforcement drive was held on June 24 and 25, during which 279 inspections were conducted at drug stores across the state. During the drive, 231 show cause notices were issued to offending establishments. In all, 15 compliance notices were served, Rao said. On digitisation of services, the minister said all applications related to blood centres are now processed through the Online National Drugs Licensing System (ONDLS) portal, with licenses issued exclusively online. In addition, an online platform has been launched to issue Recognised Medical Institution (RMI) certificates required by institutions authorised to handle essential narcotic drugs. Food samples In July, 1,557 street food vendors were inspected. Items such as fruits, vegetables, water bottles, bakery products and spice powders were checked. Of them, 406 violated safety norms. Spot fines amounting to Rs 44,500 were collected from the violators. At 186 bus stations across the state, 889 food stalls were inspected. Of them, 206 violated safety norms. Rao said as part of the drive, the department collected six samples of kebab from Empire Restaurant and all contained banned colours, including Sunset Yellow. He said the restaurant is now serving kebabs without colours. The minister also urged people to seek good quality food and report cases where they find eateries serving artificially coloured food items.
Time of India
11 hours ago
- Time of India
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Why did Hims & Hers stock fall after earnings? Live Events Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Earnings beat estimates, but Wall Street stays cautious Is the GLP‑1 weight-loss business at risk? Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Hims keeps full-year guidance intact—thanks to international expansion Subscriber growth remains strong despite volatility What investors should watch going forward Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims still growing, but cracks are showing FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever, raising questions about the future of itsDespite its rapid annual growth, Hims & Hers posted, missing the analyst estimate of. The real concern? Revenue dropped from, marking the first quarter-over-quarter decline since the company went stock currently trades at, regaining some ground after hitting an intraday low of. Despite opening at, it remains volatile, with an intraday high ofThe market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and were caught off guard, as the slowdown came amid soaring demand forlike semaglutide, a compound similar to the active ingredient in Wegovy and the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged:Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor:Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care company missed revenue estimates and saw its first-ever sequential drop in due to FDA scrutiny and legal issues around compounded semaglutide.
Time of India
11 hours ago
- Time of India
Clear labelling a must for paneer substitutes: FDA
Mumbai: The firmer variant of paneer increasingly used in institutional kitchens is not traditional milk-based paneer, but a substitute known as analogue paneer. In response to consumer complaints about misleading substitutions, the food and drugs administration (FDA) has mandated that establishments using this product must clearly display notices on premises, menus, or packaging, disclosing its composition. Although the use of cheese analogues in the food service sector has been legally permitted since 2021, FDA officials have raised concerns over their use as direct substitutes for paneer. These concerns stem from differences in their physicochemical properties and potential health implications. Hospitality sector representatives, including members of the AHAR (Association of Hotels and Restaurants) and HRAWI (Hotel and Restaurant Association of Western India), confirmed that many establishments have already implemented the required labelling protocols. Pradeep Shetty, owner of Maharaja Catering and spokesperson for HRAWI, said analogue paneer is cheaper to produce due to its use of alternative ingredients, but "menu disclosures are essential". Sudhakar Shetty, restaurateur and president of AHAR, said many major food chains are complying with the regulation, though wider public awareness is still lacking. Meanwhile, the Centre is reviewing a regulatory proposal to permit the addition of food-grade colouring agents to analogue paneer to enable easy visual differentiation from traditional paneer. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Jennifer Garner's sweet photo on sprawling family farm gets fans talking Watch More Undo You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai "Nutritionally, traditional paneer, produced by curdling milk, contains 18-20 grams of high-quality, complete protein per 100 grams, providing all nine essential amino acids necessary for muscle synthesis, tissue repair and metabolic functions," explained Rajesh Bothra, a Navi Mumbai-based nutritionist and gym trainer. "In contrast, cheese analogues typically contain only 7-10 grams of protein per 100 grams, often derived from plant sources that may lack a full amino acid profile unless specially fortified. " Nemaram Agarwal of Rajlaxmi Dairy in Powai said high consumer demand and limited supply have led some dairies to use powdered milk or even lower-quality analogue substitutes.
